TACE With Thermosensitive Nanogel Versus Embosphere for HCC

Recruiting now · Not applicable

Conditions studied: Unresectable Hepatocellular Carcinoma

In brief

To verify the safety and efficacy of TACE withThermosensitive Nanogel Embolic Agent for HCC.

Key facts

Study ID
NCT06593964
Run by
Zhongda Hospital
People needed
188
Starts
2024-09-10
Expected to finish
2026-04-30
Last updated by the study team
2024-09-19

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.